Comparison of the different oxygen delivery and ventilatory support methods for treating patients with COVID-19 induced type 1 hypoxemic respiratory failure


oxygen delivery
hypoxic respiratory failure


Having claimed the lives of over five million people in the span of two years, SARS-COV-2 caused a global health crisis and a debate between clinicians on the best respiratory interventions to use in fighting this disease. This paper aims to evaluate the different methods of respiratory support at a clinician’s disposal when treating COVID-19 induced type 1 hypoxemic respiratory failure. Data was acquired by running a literature search on MEDLINE and Web of Science using terms such as “COVID-19”, “Mortality”, “CPAP”, “Outcomes”. From 355 papers found, 11 are included in this paper. Studies have shown both CPAP and HFNO are effective when treating mild hypoxemia in COVID-19 patients, however if they fail, then chances of patient survival are slim, even if a patient’s treatment is escalated. The literature has shown that mechanical ventilation has a slightly higher survival rate than both CPAP and HFNO when used as a primary treatment and patients who are escalated to mechanical ventilation have a slim chance of survival. Considering the findings, it is crucial that clinicians consider factors such as a patient’s initial PaO2/
FiO2 as well as age when deciding on whether a patient should be ventilated or treated with CPAP or HFNO.


WHO. Coronavirus disease (COVID-19) 2021. Available from: (accessed 01 December 2021).

Parasher A. COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J.2021;97(1147):312-20. Available from:

Trougakos IP, Stamatelopoulos K, Terpos E, al. Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. J Biomed Sci. 2021;28(1):9. Available from:

Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. New Engl J Med.2020;383(25):2451-60. Available from:

Kumar M, Al Khodor S. Pathophysiology and treatment strategies for COVID-19. J Transl Med. 2020;18(1):353. Available from:

John Hopkins Coronavirus Resource Center. COVID-19 Dashboard by the Center for Systems Science and Engineering at John Hopkins University. Available from: (accessed on 01 December 2021).

Shebl E, Burns B. Respiratory failure. StatPearls. Treasure Island (FL): StatPearls Publishing. 2021.

Roussos C, Koutsoukou A. Respiratory failure. Eur Respir J Suppl. 2003;22(47 suppl):3s-14s. Available from:

Piraino T. Noninvasive respiratory support in acute hypoxemic respiratory failure. Respir Care. 2019;64(6):638-46. Available from:

Pinto VL, Sharma S. Continuous positive airway pressure. StatPearls. Treasure Island (FL): StatPearls Publishing. 2021.

Walter JM, Corbridge TC, Singer BD. Invasive mechanical ventilation. South Med J. 2018;111(12):746-53. Available from:

Vijayanand P, Wilkins E, Woodhead M. Severe acute respiratory syndrome (SARS): a review. Clin Med (Lond). 2004;4(2):152-60. Available from:

Hu L, Chen S, Fu Y, et al. Risk factors associated with clinical outcomes in 323 Coronavirus Disease 2019 (COVID-19) hospitalized patients in Wuhan, China. Clin Infect Dis. 2020;71(16):2089-98. Available from:

Nightingale R, Nwosu N, Kutubudin F, et al. Is continuous positive airway pressure (CPAP) a new standard of care for type 1 respiratory failure in COVID-19 patients? A retrospective observational study of a dedicated COVID-19 CPAP service. BMJ Open Respir Res. 2020;7(1):e000639. Available from:

Bradley P, Wilson J, Taylor R, et al. Conventional oxygen therapy versus CPAP as a ceiling of care in ward-based patients with COVID-19: a multi-centre cohort evaluation. EClinicalMedicine. 2021;40:101122-. Available from:

Perkins GD, Ji C, Connolly BA, et al. An adaptive randomized controlled trial of non-invasive respiratory strategies in acute respiratory failure patients with COVID-19. medRxiv. 2021:2021.08.02.21261379. Available from:

Wang K, Zhao W, Li J, Shu W, Duan J. The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus infected pneumonia in two hospitals of Chongqing, China. Ann Intensive Care. 2020;10(1):37. Available from:

Issa I, Söderberg M. High-flow nasal oxygen (HFNO) for patients with Covid-19 outside intensive care units. Respir Med. 2021;187:106554. Available from:

Calligaro GL, Lalla U, Audley G, et al. The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in a resource constrained setting: A multi-centre prospective observational study. EClinicalMedicine. 2020;28. Available from:

Kljakovic Gaspic T, Pavicic Ivelja M, Kumric M, et al. In-hospital mortality of COVID-19 patients treated with high-flow nasal oxygen: evaluation of biomarkers and development of the novel risk score model CROW-65. Life (Basel) 2021;11(8):735. Available from:

Avdeev SN, Yaroshetskiy AI, Tsareva NA, et al. Noninvasive ventilation for acute hypoxemic respiratory failure in patients with COVID-19. Am J Emerg Med. 2021;39:154-7. Available from:

Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323(20):2052-9. Available from:

Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle Region — case series. N Engl J Med. 2020;382(21):2012-22. Available from:

ICNARC. ICNARC report on COVID-19 in critical care: England, Wales and Northern Ireland 26 November 2021. Available from: (accessed 31 August 2023).

Chopra V, Flanders SA, Vaughn V, et al. Variation in COVID-19 characteristics, treatment and outcomes in Michigan: an observational study in 32 hospitals. BMJ Open. 2021;11(7):e044921. Available from: